OBSV ObsEva SA

7.09
0  -4%
Previous Close 7.40
Open 7.33
Price To book 0.63
Market Cap 28.85M
Shares 4,069,000
Volume 6,740
Short Ratio 0.33
Av. Daily Volume 101,162

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint in 2016. Phase 3 European trial initiation announced March 7, 2017.
OBE001 (nolasiban)
IVF
Phase 3 trial to be initiated 1H 2017 with data due 1H 2020.
OBE2109 - PRIMROSE
Uterine fibroids
Phase 2b data due 1H 2018.
OBE2109 - EDELWEISS
Endometriosis